M. Moore

发表

Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group

P. Murawa, K. Ding, W. Parulekar, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer

M. Tsao, O. Ludkovski, D. Tu, 2010, Cancer.

Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer

M. Piccart, C. Takimoto, M. Moore, 2006, Clinical Cancer Research.

Cetuximab for the treatment of colorectal cancer.

Dongsheng Tu, John R Zalcberg, R. Simes, 2007, The New England journal of medicine.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Dongsheng Tu, John R Zalcberg, Lois Shepherd, 2008, The New England journal of medicine.

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer.

Sergio Ricci, S. Ricci, M. Moore, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pan-cancer analysis of whole genomes

Steven J. M. Jones, Nuno A. Fonseca, Icgc, 2020, Nature.

Randomized phase II trials: inevitable or inadvisable?

D. Sargent, G. Pond, M. Moore, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Development of quality indicators of care for patients undergoing hepatic resection for metastatic colorectal cancer using a Delphi process.

J. Barkun, G. Maddern, M. Sherman, 2009, The Journal of surgical research.

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial.

John R. Mackey, Fiona Campbell, David Goldstein, 2014, Journal of the National Cancer Institute.

A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium

I. Tannock, Lisa I. Wang, A. Eisen, 2011, Investigational New Drugs.

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer.

Daniel J Sargent, Dongsheng Tu, Pierre Laurent-Puig, 2003, The New England journal of medicine.

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.

D. V. Von Hoff, M. Moore, E. Casper, 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

D. V. Von Hoff, M. Moore, H. Burris, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

David Goldstein, Manuel Hidalgo, Thomas Ervin, 2013, The New England journal of medicine.

NRG1 Gene Fusions Are Recurrent, Clinically Actionable Gene Rearrangements in KRAS Wild-Type Pancreatic Ductal Adenocarcinoma

Steven J. M. Jones, Richard A. Moore, E. Pleasance, 2019, Clinical Cancer Research.

Advanced pancreatic carcinoma: current treatment and future challenges

M. Moore, A. Stathis, Malcolm J. Moore, 2010, Nature Reviews Clinical Oncology.

Changing the Way We Do Business: Recommendations to Accelerate Biomarker Development in Pancreatic Cancer

J. Berlin, D. Klimstra, M. Tempero, 2013, Clinical Cancer Research.

A Phase I trial of prolonged administration of lovastatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or of the cervix.

A. Oza, M. Moore, S. Kamel‐Reid, 2005, European journal of cancer.

Predictive Biomarkers and Personalized Medicine PIK 3 CA , BRAF , andPTENStatus andBene fi t fromCetuximab in the Treatment of Advanced Colorectal Cancer — Results from NCIC CTG / AGITG CO . 17

P. Gibbs, N. Pavlakis, D. Tu, 2014 .

CTG / AGITG CO . 17 Results from NCIC − − Treatment of Advanced Colorectal Cancer , and PTEN Status and Benefit from Cetuximab in the PIK 3 CA , BRAF

M. Moore, J. Zalcberg, J. Simes, 2014 .

PIK3CA, BRAF, and PTEN Status and Benefit from Cetuximab in the Treatment of Advanced Colorectal Cancer—Results from NCIC CTG/AGITG CO.17

P. Gibbs, N. Pavlakis, D. Tu, 2013, Clinical Cancer Research.

Clinical studies.

G. Pond, A. Oza, J. Dancey, 2000, Women alive.

Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.

A. Oza, D. Hedley, M. Moore, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of cisplatin, irinotecan, and epirubicin administered every 3 weeks in patients with advanced solid tumours

A. Oza, M. Moore, L. Siu, 2003, British Journal of Cancer.

Molecular Profiling of Patients With Advanced Colorectal Cancer: Princess Margaret Cancer Centre Experience

H. Mackay, M. Tsao, D. Hedley, 2017, Clinical colorectal cancer.

A phase II study of Temozolomide in advanced untreated pancreatic cancer

A. Oza, D. Hedley, M. Moore, 2004, Investigational New Drugs.

Depression and use of health care services in patients with advanced cancer.

F. Shepherd, P. Kurdyak, M. Moore, 2013, Canadian family physician Medecin de famille canadien.

Randomized, double-blind, placebo-controlled trial of epoetin alfa in men with castration-resistant prostate cancer and anemia.

M. Moore, M. Levine, E. Winquist, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Determination of GTI-2040, a novel antisense oligonucleotide, in human plasma by using HPLC combined with solid phase and liquid-liquid extractions.

M. Moore, N. Leighl, E. Chen, 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Latency and interval therapy affect the evolution in metastatic colorectal cancer

M. Moore, S. Kamel‐Reid, L. Siu, 2020, Scientific Reports.

A phase II, multicenter study of cetuximab monotherapy in patients with refractory, metastatic colorectal carcinoma with absent epidermal growth factor receptor immunostaining

M. Moore, E. Rowinsky, D. Jonker, 2011, Investigational New Drugs.

Activity of gemcitabine in patients with advanced pancreatic carcinoma: A review

M. Moore, 1996, Cancer.

Comparison of 99mTc-sestamibi and doxorubicin to monitor inhibition of P-glycoprotein function

D. Hedley, M. Moore, J. Ballinger, 2001, British Journal of Cancer.

Treatment burden in stage I seminoma: a comparison of surveillance and adjuvant radiation therapy

P. Warde, T. Panzarella, M. Gospodarowicz, 2013, BJU international.

Phase II Clinical and Pharmacokinetic Study of Aflibercept in Patients with Previously Treated Metastatic Colorectal Cancer

A. Chen, Lisa I. Wang, M. Moore, 2012, Clinical Cancer Research.

Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17.

P. Gibbs, N. Pavlakis, J. Meharchand, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose-dependent Increases in Circulating Tgf-a and Other Egfr Ligands Act as Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent Cancer Therapy: Preclinical

R. Kerbel, M. Moore, Christina R. Lee, 2022 .

Sucralfate mouthwash for prevention and treatment of 5-fluorouracil-induced mucositis: a randomized, placebo-controlled trial

G. Pond, A. Oza, D. Hedley, 2002, Supportive Care in Cancer.

Outcome and toxicity of postoperative short course adjuvant radiation and chemotherapy following resection of adenocarcinoma of the rectum

J. Brierley, M. Moore, M. Pintilie, 2004, Acta oncologica.

Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.

R. Labianca, V. Torri, E. Van Cutsem, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Arterial thrombosis after cisplatin-based chemotherapy for metastatic germ cell tumors

M. Moore, I. Durán, D. Berthold, 2009, Acta oncologica.

A phase II multicenter study of cetuximab monotherapy in patients with EGFR-undetectable refractory metastatic colorectal carcinoma (mCRC)

M. Moore, E. Rowinsky, D. Jonker, 2008 .

Phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with metastatic (MET) chemotherapy refractory K-RAS wild-type (WT) colorectal carcinoma (CRC): The NCIC Clinical Trials Group and AGITG CO.20 trial.

M. Sawyer, D. Tu, M. Moore, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Conformal radiotherapy in the adjuvant treatment of gastric cancer: Review of 82 cases.

A. Oza, G. Lockwood, Z. Kassam, 2006, International journal of radiation oncology, biology, physics.

Combining gemcitabine and capecitabine in patients with advanced biliary cancer: a phase II trial.

G. Pond, A. Oza, D. Hedley, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Impact of opening an acute palliative care unit on administrative outcomes for a general oncology ward

M. Moore, M. Krzyzanowska, G. Rodin, 2008, Cancer.

The relationship of K-ras mutations and EGFR gene copy number to outcome in patients treated with Erlotinib on National Cancer Institute of Canada Clinical Trials Group trial study PA.3

M. Tsao, O. Ludkovski, D. Tu, 2007 .

Chemotherapy in Prostate Cancer

M. Moore, S. Sridhar, 2005 .

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer

Y. Yen, Lisa I. Wang, M. Moore, 2011, Cancer Chemotherapy and Pharmacology.

Population Pharmacokinetics of Troxacitabine, a Novel Dioxolane Nucleoside Analogue

M. Hidalgo, M. Moore, S. Baker, 2006, Clinical Cancer Research.

Epidermal growth factor receptor expression in anal canal carcinoma.

M. Moore, R. Chetty, L. Lê, 2005, American journal of clinical pathology.

Problems Associated with the Assessment of Patients with Metastatic Breast Cancer: Can Past Experience Teach us to do Better Clinical Trials?

I. Tannock, M. Moore, 1987 .

Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer.

I. Tannock, M. Moore, N. Murray, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Quality of life in patients with advanced colorectal cancer treated with cetuximab: Results of the NCIC CTG and AGITG CO.17 trial

D. Tu, H. Kennecke, M. Moore, 2007 .

Multicenter Phase II Trial of Temsirolimus and Bevacizumab in Pancreatic Neuroendocrine Tumors.

Helen X. Chen, H. Lenz, M. Moore, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prostate cancer: 9. Treatment of advanced disease.

M. Gleave, N. Bruchovsky, M. Moore, 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials.

I. Tannock, G. Pond, M. Moore, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Results of a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas with PET and CA19-9 correlates.

M. Hidalgo, M. Reni, J. Tabernero, 2013 .

Rapid development of enhanced clearance after high‐dose cyclophosphamide

M. Moore, C. Erlichman, J. Thiessen, 1988, Clinical pharmacology and therapeutics.

Variability in the pharmacokinetics of cyclophosphamide, methotrexate and 5-fluorouracil in women receiving adjuvant treatment for breast cancer

M. Moore, C. Erlichman, J. Thiessen, 2004, Cancer Chemotherapy and Pharmacology.

AVANT: Results from a randomized, three-arm multinational phase III study to investigate bevacizumab with either XELOX or FOLFOX4 versus FOLFOX4 alone as adjuvant treatment for colon cancer.

E. Van Cutsem, J. Tabernero, M. Makrutzki, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT).

M. Hidalgo, M. Reni, E. Van Cutsem, 2013 .

FOLFIRINOX for advanced pancreatic cancer

D. Hedley, Lisa I. Wang, M. Moore, 2016 .

FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience

D. Hedley, Lisa I. Wang, M. Moore, 2016, British Journal of Cancer.

Role of glutathione S-transferases in the resistance of human colon cancer cell lines to doxorubicin.

M. Moore, Kamran Ahmad, K. Ahmad, 1998, Cancer research.

Long-term outcome of radiation-based conservation therapy for invasive bladder cancer.

I. Tannock, R. Bristow, C. Catton, 2007, Urologic oncology.

Original article Long-term outcome of radiation-based conservation therapy for invasive bladder cancer

I. Tannock, R. Bristow, C. Catton, 2007 .

Postmenopausal oestradiol-dydrogesterone therapy favourably affects fibrinolysis and Lp(a) in healthy women

M. Moore, C. Stehouwer, P. Kenemans, 1999 .

Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial

Allan Donner, I. Tannock, A. Oza, 2014, The Lancet.

The role of systemic chemotherapy in the management of muscle-invasive bladder cancer.

I. Tannock, M. Moore, H. Juffs, 2002, The Lancet. Oncology.

Adjuvant chemotherapy for high-risk urothelial transitional cell carcinoma: the Princess Margaret Hospital experience.

I. Tannock, M. Moore, M. Michael, 1998, British journal of urology.

Novel targets in prostate cancer

M. Moore, D. Berthold, 2006, Expert opinion on therapeutic targets.

Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.

D. Hedley, M. Moore, S. Gallinger, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP)

M. Moore, D. Goldstein, D. Vernerey, 2016, British Journal of Cancer.

Cost-effectiveness of FOLFIRINOX for first-line treatment of metastatic pancreatic cancer.

M. Moore, Stephen T Brown, K. Alloul, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Reply: Evaluating the activity of temsirolimus in neuroendocrine cancer

M. Moore, L. Siu, I. Durán, 2006, British Journal of Cancer.

A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer.

M. Piccart, C. Takimoto, M. Moore, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term survival results of a randomized trial comparing gemcitabine/cisplatin and methotrexate/vinblastine/doxorubicin/cisplatin in patients with locally advanced and metastatic bladder cancer.

M. Moore, P. Conte, H. von der Maase, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer

S. Ricci, M. Moore, L. Sengeløv, 2005 .

Neoadjuvant treatment for pancreatic cancer--a review.

L. Dawson, M. Moore, A. Wei, 2008, Critical reviews in oncology/hematology.

Use of the somatostatin analogue octreotide acetate in the treatment of encephalopathy associated with carcinoid tumor. Case report.

M. Moore, L. Siu, W. Chapman, 1997, American journal of clinical oncology.

Phase I study of the multidrug resistance inhibitor zosuquidar administered in combination with vinorelbine in patients with advanced solid tumours

A. Oza, L. Seymour, M. Moore, 2005, Cancer Chemotherapy and Pharmacology.

High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy.

I. Tannock, M. Moore, P. Czaykowski, 1998, The Journal of urology.

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.

Jeffrey W. Clark, H. Hirte, H. Lenz, 2007, The oncologist.

Post-operative radiochemotherapy for gastric cancer: adoption and adaptation.

A. Oza, D. Hedley, J. Brierley, 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer

G. Pond, A. Oza, J. Dancey, 2006, British Journal of Cancer.

A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma.

I. Tannock, M. Moore, N. Iscoe, 1993, The Journal of urology.

Canadian consensus guidelines for the management of testicular germ cell cancer.

R. Huddart, P. Albers, P. Warde, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

A phase II study of 5‐fluorouracil, leucovorin and interferon‐α in advanced pancreatic cancer

M. Moore, C. Erlichman, L. Kaizer, 1993 .

A phase II study of 5-fluorouracil, leucovorin and interferon-alpha in advanced pancreatic cancer.

M. Moore, C. Erlichman, L. Kaizer, 1993, Anti-cancer drugs.

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

P. Albers, M. Moore, I. Bodrogi, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer.

L. Seymour, M. Moore, W. Stadler, 2002, Urologic oncology.

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group.

I. Tannock, L. Seymour, M. Moore, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A meta-analysis of two randomised trials of early chemotherapy in asymptomatic metastatic colorectal cancer

R. Goldberg, D. Tu, M. Moore, 2005, British Journal of Cancer.

Pancreatic cancer: what the oncologist can offer for palliation.

M. Moore, 2002, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

Phase II trial of aflibercept (VEGF Trap) in previously treated patients with metastatic colorectal cancer (MCRC): A PMH phase II consortium trial

A. Chen, Lisa I. Wang, M. Moore, 2008 .

Utility of serum tumor markers during surveillance for stage I seminoma

P. Warde, T. Panzarella, M. Gospodarowicz, 2012, Cancer.

Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience.

G. Pond, A. Oza, D. Hedley, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials

M. Büchler, D. Smith, J. Neoptolemos, 2009, British Journal of Cancer.

No role for routine chest radiography in stage I seminoma surveillance.

P. Warde, T. Panzarella, M. Gospodarowicz, 2010, European urology.

Natural history and chemotherapy effectiveness for advanced adenocarcinoma of the small bowel: a retrospective review of 113 cases.

G. Pond, A. Oza, M. Moore, 2006, American journal of clinical oncology.

99Tcm-sestamibi imaging of inhibition of the multidrug resistance transporter in a mouse xenograft model of human breast cancer.

M. Moore, J. Ballinger, T. Muzzammil, 1999, Nuclear medicine communications.

Overview of Canadian trials in hormonally resistant prostate cancer.

I. Tannock, M. Moore, 1996, Seminars in oncology.

Cost-effectiveness of folfirinox for first-line treatment of metastatic pancreatic cancer.

M. Moore, K. Alloul, C. Attard, 2013, Current oncology.

Systemic Therapy of Bladder Cancer

M. Moore, 2000 .

Initial versus recent outcomes with a non–risk adapted surveillance policy in stage I non-seminomatous germ cell tumors (NSGCT)

G. Pond, P. Warde, M. Moore, 2007 .

Compliance and outcome of patients with stage 1 non-seminomatous germ cell tumors (NSGCT) managed with surveillance programs in seven Canadian centres.

M. Moore, E. Winquist, D. Hao, 2005, The Canadian journal of urology.

Appropriate radiation volume for stage IIA/B testicular seminoma.

C. Catton, P. Warde, T. Panzarella, 2003, International journal of radiation oncology, biology, physics.

Treatment of metastatic bladder cancer in the elderly

M. Moore, 1993 .

Impact of Granulocyte‐colony Stimulating Factor on Bleomycin‐induced Pneumonitis in Chemotherapy‐treated Germ Cell Tumors

P. Warde, M. Moore, Philippe Bédard, 2017, Clinical genitourinary cancer.

Location of colon cancer (right-sided [RC] versus left-sided [LC]) as a predictor of benefit from cetuximab (CET): NCIC CTG CO.17.

D. Tu, M. Moore, J. Zalcberg, 2013 .

Phase II Study of Trimetrexate in Recurrent Anaplastic Glioma: National Cancer Institute of Canada Clinical Trials Group Study

J. Cairncross, E. Eisenhauer, D. Macdonald, 1990, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575)

A. Oza, B. Clarke, H. Hirte, 2013, Investigational New Drugs.

PANCREOX: A randomized phase 3 study of 5FU/LV with or without oxaliplatin for second-line advanced pancreatic cancer (APC) in patients (pts) who have received gemcitabine (GEM)-based chemotherapy (CT).

M. Moore, S. Gill, Y. Ko, 2014 .

A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over

B. Leber, M. Minden, M. Moore, 2009, Leukemia.

A phase II, open-label study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC): CP12-0709/NCT00862784.

J. Tabernero, M. Moore, F. Rivera, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Large retroperitoneal lymphadenopathy as a predictor of venous thromboembolism in patients with disseminated germ cell tumors treated with chemotherapy.

P. Warde, M. Moore, Philippe Bédard, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.

L. Dawson, P. Lindsay, Z. Kassam, 2014, International journal of radiation oncology, biology, physics.

In vitro comparison of sestamibi, tetrofosmin, and furifosmin as agents for functional imaging of multidrug resistance in tumors.

M. Moore, J. Ballinger, T. Muzzammil, 2000, Cancer biotherapy & radiopharmaceuticals.

Activity of cediranib (AZD2171) in patients (pts) with previously untreated metastatic renal cell cancer (RCC). A phase II trial of the PMH Consortium

M. Haider, Lisa I. Wang, M. Moore, 2008 .

A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer.

M. Sawyer, W. Miller, M. Moore, 2014 .

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

D. Osoba, I. Tannock, M. Stockler, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Should surveillance be considered the standard of care in stage I seminoma

C. Catton, P. Warde, T. Panzarella, 2005 .

Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection.

M. Moore, L. Siu, E. Chen, 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Treatment of hormone refractory prostate cancer.

M. Moore, J. Knox, 2001, Seminars in urologic oncology.

A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer

M. Moore, W. Vervenne, C. Verslype, 2008 .

Maintenance of progesterone-facilitated sexual behavior in female rats requires continued hypothalamic protein synthesis and nuclear progestin receptor occupation.

M. Moore, J. Blaustein, T. Brown, 1987, Endocrinology.

Economic evaluation of chemotherapy with mitoxantrone plus prednisone for symptomatic hormone-resistant prostate cancer: based on a Canadian randomized trial with palliative end points.

A R Willan, I. Tannock, T. Smith, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET).

Helen X. Chen, H. Lenz, M. Moore, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II study of GTI-2040 plus docetaxel as 2nd-line treatment in non-small cell lung cancer (NSCLC) and other solid tumors

G. Pond, F. Shepherd, P. Ellis, 2005 .

The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17.

P. Gibbs, N. Pavlakis, J. Meharchand, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first line treatment in hormone refractory prostate cancer (HRPC).

G. Pond, M. Moore, S. Hotte, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of the angiogenesis inhibitor AZD2171 in first line, progressive, unresectable, advanced metastatic renal cell carcinoma (RCC): A trial of the PMH Phase II Consortium

G. Pond, M. Haider, M. Moore, 2007 .

Phase I-II study of 5-fluorouracil, leucovorin, doxorubicin, methotrexate, and long-term oral etoposide (FLAME) in unresectable or metastatic gastric cancer.

A. Oza, M. Moore, E. Franssen, 1998, American journal of clinical oncology.

Should my accountant sing La Traviata at the Met?

M. Moore, B. Šeruga, B. Seruga, 2013, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.

D. Tu, M. Moore, J. Zalcberg, 2015, European journal of cancer.

Feasibility and benefits of second-line chemotherapy in advanced biliary tract cancer: a large retrospective study.

H. Mackay, D. Hedley, M. Moore, 2012, European journal of cancer.

A phase II study of capecitabine, irinotecan, and bevacizumab (XELIRI-A) in patients (pts) with previously untreated metastatic colorectal cancer (mCRC).

H. Mackay, M. Moore, S. Welch, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Joon-Oh Park, J. Berlin, A. Biankin, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial of R115777, an oral farnesyl transferase inhibitor, in patients with advanced urothelial tract transitional cell carcinoma

E. Small, J. Pérez-Ruixo, J. Rosenberg, 2005, Cancer.

High epiregulin (EREG) gene expression plus K-ras wild-type (WT) status as predictors of cetuximab benefit in the treatment of advanced colorectal cancer (ACRC): Results from NCIC CTG CO.17-A phase III trial of cetuximab versus best supportive care (BSC).

R. Simes, D. Tu, M. Moore, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial.

P. Gibbs, D. Tu, M. Moore, 2009, Journal of the National Cancer Institute.

Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.

L. Saltz, C. Blanke, M. Moore, 2000, The New England journal of medicine.

Invasive pulmonary aspergillosis associated with marijuana use in a man with colorectal cancer.

D. Cescon, M. Moore, W. Gold, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Alternate Endpoints for Screening Phase II Studies

Daniel J Sargent, Dongsheng Tu, Lesley Seymour, 2009, Clinical Cancer Research.

Prognostic factors for relapse in stage I testicular seminoma treated with surveillance.

C. Catton, P. Warde, T. Panzarella, 1997, The Journal of urology.

Use of mesna to prevent ifosfamide-induced urotoxicity

M. Moore, L. Siu, 1998, Supportive Care in Cancer.

Eyelid metastasis from mediastinal teratoma with malignant transformation

M. Moore, I. Durán, D. Berthold, 2007, Acta oncologica.

Phase I and Pharmacologic Study of the Human DNA Methyltransferase Antisense Oligodeoxynucleotide MG98 given as a 21-day Continuous Infusion Every 4 Weeks

E. Eisenhauer, K. Gelmon, M. Moore, 2003, Investigational New Drugs.

Therapeutic Drug Monitoring in Oncology

M. Moore, C. Erlichman, 1987, Clinical pharmacokinetics.

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.

J. Hecht, R. Salazar, E. Van Cutsem, 2012, The Lancet. Oncology.

Exome-Wide Association Study of Pancreatic Cancer Risk.

Lincoln D. Stein, A. Klein, A. Biankin, 2017, Gastroenterology.

Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers

R. Gershoni-baruch, E. Dagan, E. Friedman, 2014, British Journal of Cancer.

Patterns of somatic structural variation in human cancer genomes

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2020, Nature.

Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma

Lincoln D. Stein, J. McPherson, D. Durocher, 2017, JAMA oncology.

DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy.

R. Labianca, D. Sargent, S. Thibodeau, 2011, Journal of the National Cancer Institute.

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2020, Nature Communications.

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild‐type BRCA pancreatic ductal adenocarcinoma

Laura H. Tang, A. Chen, Z. Stadler, 2018, Cancer.

Genomics-Driven Precision Medicine for Advanced Pancreatic Cancer: Early Results from the COMPASS Trial

R. Moffitt, F. Notta, J. Yeh, 2017, Clinical Cancer Research.

Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial.

H. Friess, M. Büchler, J. Neoptolemos, 2010, JAMA.

A multi‐institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer

Edward J. Kim, K. Griffith, I. Francis, 2013, Cancer.

A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer.

L. Seymour, H. Hirte, M. Moore, 2005, Urologic oncology.

Concurrent gemcitabine and radiotherapy with and without neoadjuvant gemcitabine for locally advanced unresectable or resected pancreatic cancer: a phase I-II study.

G. Pond, A. Oza, D. Hedley, 2007, International journal of radiation oncology, biology, physics.

A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer

Joseph L. Chin, John Trachtenberg, Lisa Wang, 2010, American journal of clinical oncology.

A review of erlotinib and its clinical use

Ming-Sound Tsao, M. Tsao, M. Moore, 2006, Expert opinion on pharmacotherapy.

A case of small bowel obstruction due to intraluminal metastases from metastatic renal cell cancer.

M. Haider, M. Moore, S. Sridhar, 2008, The oncologist.

Metastatic Renal Cell Cancer A Case of Small Bowel Obstruction Due to Intraluminal Metastases from

M. Haider, M. Moore, S. Sridhar, 2008 .

Latency and interval therapy affect the evolution in metastatic colorectal cancer

M. Moore, S. Kamel‐Reid, L. Siu, 2020, Scientific Reports.

Predictors of referral for specialized psychosocial oncology care in patients with metastatic cancer: the contributions of age, distress, and marital status.

F. Shepherd, M. Moore, G. Rodin, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Unresectable Pancreatic Cancer

L. Dawson, M. Moore, D. Renouf, 2011 .

Altered Gene Expression along the Glycolysis–Cholesterol Synthesis Axis Is Associated with Outcome in Pancreatic Cancer

Steven J. M. Jones, Richard A. Moore, M. Marra, 2019, Clinical Cancer Research.

Phase I and pharmacologic study of 9-aminocamptothecin colloidal dispersion formulation given as a 24-hour continuous infusion weekly times four every 5 weeks.

E. Eisenhauer, A. Oza, M. Moore, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Trial.

M. Sawyer, D. Tu, M. Moore, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.

J. Dancey, L. Seymour, D. Tu, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer

R. Simes, D. Tu, M. Moore, 2013, British Journal of Cancer.

Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial.

M. Büchler, J. Neoptolemos, M. Lerch, 2012, JAMA.

A phase I trial of doxorubicin (DOX) and PSC 833, a modulator of multidrug resistance (MDR): 97

P. Goodman, M. Moore, C. Erlichman, 1994 .

Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer

J. Berlin, J. Ajani, P. Philip, 2006, Cancer.

Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors.

A. Oza, E. Warner, M. Moore, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience.

G. Pond, P. Warde, M. Gospodarowicz, 2011, European urology.

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.

I. Tannock, K. Ding, W. Parulekar, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase II study of oxaliplatin in urothelial cancer.

L. Schumm, E. Vokes, M. Moore, 2005, Urologic oncology.

Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer.

W. Scheithauer, E. Van Cutsem, M. Moore, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial.

A. Carrato, L. Lipton, C. Fuchs, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Outcome of Adjuvant Therapy in Biliary Tract Cancers

L. Dawson, D. Hedley, M. Moore, 2015, American journal of clinical oncology.

Expanded Low Allele Frequency RAS and BRAF V600E Testing in Metastatic Colorectal Cancer as Predictive Biomarkers for Cetuximab in the Randomized CO.17 Trial

D. Tu, S. Kopetz, H. Kennecke, 2020, Clinical Cancer Research.

Perioperative Gemcitabine + Erlotinib Plus Pancreaticoduodenectomy for Resectable Pancreatic Adenocarcinoma: ACOSOG Z5041 (Alliance) Phase II Trial

D. Sahani, J. Meyerhardt, Douglas B. Evans, 2019, Annals of Surgical Oncology.

A phase II study of erlotinib in gemcitabine refractory advanced pancreatic cancer.

M. Tsao, D. Hedley, M. Moore, 2014, European journal of cancer.

Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study

E. Van Cutsem, M. Moore, T. Ciuleanu, 2014, British Journal of Cancer.

A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer.

M. Sawyer, W. Miller, M. Moore, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Pharmacokinetics of Cyclophosphamide

M. Moore, 1991, Clinical pharmacokinetics.

Differential sensitivity of various pediatric cancers and squamous cell carcinomas to lovastatin-induced apoptosis: therapeutic implications.

L. Penn, M. Moore, S. Kamel‐Reid, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I and Pharmacokinetic Study of Fostriecin given as an Intravenous Bolus Daily for Five Consecutive Days

E. Eisenhauer, M. Moore, C. Erlichman, 2004, Investigational New Drugs.

A clinical and pharmacological study of 5-fluorouracil, leucovorin and interferon alfa in advanced colorectal caner

M. Moore, C. Erlichman, R. Feld, 2004, Cancer Chemotherapy and Pharmacology.

Choice of starting dose for molecularly targeted agents evaluated in first-in-human phase I cancer clinical trials.

M. Moore, A. Stathis, L. Siu, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epidermal Growth Factor Receptor Antagonists in Pancreatic Cancer

M. Moore, P. Tang, 2006 .

A Novel Biomarker Panel Examining Response to Gemcitabine with or without Erlotinib for Pancreatic Cancer Therapy in NCIC Clinical Trials Group PA.3

Albert C. Koong, Dongsheng Tu, Daniel T. Chang, 2016, PloS one.

Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.

L. Seymour, M. Brundage, M. Moore, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo.

D. Tu, W. Parulekar, M. Moore, 2012, European journal of cancer.

The palliative benefit of irinotecan in 5-fluorouracil-refractory colorectal cancer: its prospective evaluation by a Multicenter Canadian Trial.

A. Oza, D. Hedley, M. Moore, 2002, Clinical colorectal cancer.

Phase II trial of pegylated-liposomal doxorubicin in the treatment of locally advanced unresectable or metastatic transitional cell carcinoma of the urothelial tract.

G. Lockwood, M. Moore, R. Segal, 2003, European journal of cancer.

How expert physicians would wish to be treated if they had genitourinary cancer.

I. Tannock, B. O'Sullivan, M. Moore, 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Do Correlates of Pain-Related Stoicism and Cautiousness Differ in Younger and Older People With Advanced Cancer?

F. Shepherd, M. Moore, G. Rodin, 2017, The journal of pain : official journal of the American Pain Society.

Management of pancreatic adenocarcinoma in Ontario, Canada: a population-based study using novel case ascertainment.

D. Urbach, M. Moore, S. Gallinger, 2011, Canadian journal of surgery. Journal canadien de chirurgie.

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

D. Osoba, I. Tannock, K. Murphy, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant therapy and major arterial resection for potentially reconstructable arterial involvement by stage 3 adenocarcinoma of the pancreas.

C. Moulton, John J. Kim, M. Moore, 2019, HPB : the official journal of the International Hepato Pancreato Biliary Association.

An open-label phase II study evaluating the safety and efficacy of ramucirumab combined with mFOLFOX-6 as first-line therapy for metastatic colorectal cancer.

J. Tabernero, M. Moore, J. Maurel, 2014, The oncologist.

Assessing the impact of chemotherapy on tumor-related symptoms in advanced colorectal cancer.

M. Moore, M. Michael, 1998, Oncology.

Combination Chemotherapy and ALVAC-CEA/B7.1 Vaccine in Patients with Metastatic Colorectal Cancer

A. Benson, H. Lenz, J. Marshall, 2008, Clinical Cancer Research.

From trial to practice: The Princess Margaret Hospital (PMH) experience with docetaxel and prednisone for men with metastatic castration resistant prostate cancer (mCRPC).

I. Tannock, M. Moore, J. Knox, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Interleukin-2 in the treatment of unresectable or metastatic renal cell cancer: Time to write the obituary?

M. Moore, 2012, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours

M. Moore, A. Stathis, L. Siu, 2013, British Journal of Cancer.

Determination of Lovastatin in Human Plasma Using Reverse-Phase High-Performance Liquid Chromatography With UV Detection

M. Moore, P. Firby, L. Ye, 2000, Therapeutic drug monitoring.

A Phase 2 study of perifosine in advanced or metastatic breast cancer

G. Pond, J. Dancey, D. Hedley, 2008, Breast Cancer Research and Treatment.

Survival Following Resection of Intra- and Extra-Hepatic Metastases from Colorectal Cancer: A Phase II Trial

C. Moulton, M. Moore, S. Gallinger, 2016, Annals of surgical oncology.

N. Pavlakis, M. Brundage, D. Tu, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I/II study of the Src inhibitor saracatinib (AZD0530) in combination with gemcitabine in advanced pancreatic cancer

L. Seymour, D. Hedley, M. Moore, 2012, Investigational New Drugs.

Screening for Pancreatic Cancer in a High-Risk Cohort: An Eight-Year Experience

M. Haider, K. Jhaveri, M. Moore, 2012, Journal of Gastrointestinal Surgery.

Neuroendocrine Tumors of the Gastrointestinal Tract: A Decade of Experience at the Princess Margaret Hospital

G. Pond, J. Brierley, M. Moore, 2008, American journal of clinical oncology.

Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer

M. Moore, J. Spano, A. Ricart, 2012, Investigational New Drugs.

A phase II study of the HSP90 inhibitor AUY922 in chemotherapy refractory advanced pancreatic cancer

D. Hedley, M. Moore, M. Krzyzanowska, 2016, Cancer Chemotherapy and Pharmacology.

Psychometric Evaluation of the Pain Attitudes Questionnaire-Revised for People With Advanced Cancer.

F. Shepherd, M. Moore, G. Rodin, 2017, The journal of pain : official journal of the American Pain Society.

Longitudinal study of depressive symptoms in patients with metastatic gastrointestinal and lung cancer.

F. Shepherd, M. Moore, J. Jones, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The contribution of attachment security and social support to depressive symptoms in patients with metastatic cancer

A. Donner, M. Mikulincer, M. Moore, 2007, Psycho-oncology.

A phase III study of cetuximab (CET) plus either brivanib alaninate (BRIV) versus placebo in patients with chemotherapy-refractory KRAS wild-type (WT) advanced colorectal cancer (aCRC): The NCIC CTG/AGITG CO.20 trial.

D. Tu, M. Moore, J. Zalcberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sex differences in oncogenic mutational processes

Nuno A. Fonseca, Gary D Bader, Benjamin J. Raphael, 2019, Nature Communications.

Phase II study of bortezomib in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital [PMH] Phase II Consortium

G. Pond, E. Vokes, D. Hedley, 2005 .

Combination chemotherapy in advanced pancreatic cancer: time to raise the white flag?

M. Moore, S. Welch, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Supporting treatment decision making in advanced cancer: a randomized trial of a decision aid for patients with advanced colorectal cancer considering chemotherapy.

A. Oza, P. Butow, P. Beale, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validation of the short-form McGill pain questionnaire-2 in younger and older people with cancer pain.

R. Melzack, R. Dworkin, F. Shepherd, 2014, The journal of pain : official journal of the American Pain Society.

Short report: Multicenter phase II trial of brequinar sodium in patients with advanced melanoma

M. Moore, R. Wheeler, B. Dallaire, 1992 .

Detection of Relapse by Low-dose Computed Tomography During Surveillance in Stage I Testicular Germ Cell Tumours.

P. Warde, T. Panzarella, M. Gospodarowicz, 2019, European urology oncology.

Brief communication: a new combination in the treatment of advanced pancreatic cancer.

M. Moore, 2005, Seminars in oncology.

Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.

Laura H. Tang, A. Chen, Z. Stadler, 2018, European journal of cancer.

Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinoma.

N. Agarwal, G. Sonpavde, M. Galsky, 2013, Clinical genitourinary cancer.

HENT1 tumor levels to predict survival of pancreatic ductal adenocarcinoma patients who received adjuvant gemcitabine and adjuvant 5FU on the ESPAC trials.

M. Büchler, J. Mackey, W. Greenhalf, 2013 .

Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC).

Laura H. Tang, A. Chen, Z. Stadler, 2014 .

Pancreatic Adenocarcinoma Surveillance Counterpoint: Canada

M. Moore, A. Stathis, 2013 .

The treatment of advanced pancreatic cancer: current evidence and future challenges.

M. Moore, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Minimally Invasive Real-Time Detection of Actionable Mutations in Patients With Metastatic Solid Tumors Using Fine-Needle and Liquid Biopsies.

J. McPherson, A. Oza, H. Berman, 2018, JCO precision oncology.

A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia

G. Pond, M. Moore, J. Wright, 2006, Investigational New Drugs.

The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscle-invasive urothelial transitional cell carcinoma.

I. Tannock, M. Moore, L. Siu, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

1 DISTINCT MUTATIONAL SIGNATURES ARE ASSOCIATED WITH CORRELATES OF 1 INCREASED IMMUNE ACTIVITY IN PANCREATIC DUCTAL ADENOCARCINOMA 2 3

Lincoln D. Stein, J. McPherson, V. Ferretti, 2016 .

Predictive and prognostic features of metastatic colorectal cancer arising from the transverse colon: A pooled analysis of the CCTG/AGITG CO.17 and CO.20 randomized trials.

D. Tu, M. Moore, J. Zalcberg, 2023, Journal of Clinical Oncology.

Sorafenib for Metastatic Renal Cancer: The Princess Margaret Experience

I. Tannock, R. Riechelmann, M. Moore, 2008, American journal of clinical oncology.

Age differences in cancer pain: a pilot study

M. Moore, J. Jones, G. Rodin, 2004 .

Expanding the Role of EGFR Inhibitors in Prostate Cancer

M. Moore, S. Sridhar, 2006 .

UROLOGICAL ONCOLOGY: BLADDER, PENIS AND URETHRA CANCER, AND BASIC PRINCIPLES OF ONCOLOGY Long-Term Survival Results of a Randomized Trial Comparing Gemcitabine Plus Cisplatin, With Methotrexate, Vinblastine, Doxorubicin, Plus Cisplatin in Patients With Bladder Cancer

S. Ricci, M. Moore, L. Sengeløv, 2006 .

A phase II study of capecitabine, irinotecan, and bevacizumab in patients with previously untreated metastatic colorectal cancer

H. Mackay, M. Moore, Geoffrey Liu, 2012, Cancer Chemotherapy and Pharmacology.

Erlotinib: success of a molecularly targeted agent for the treatment of advanced pancreatic cancer.

M. Moore, S. Welch, 2007, Future oncology.

Preoperative radiation with concurrent chemotherapy for resectable rectal cancer: effect of dose escalation on pathologic complete response, local recurrence-free survival, disease-free survival, and overall survival.

G. Pond, A. Oza, John J. Kim, 2006, International Journal of Radiation Oncology, Biology, Physics.

Phase II trial of erlotinib in advanced pancreatic cancer (PC).

D. Hedley, M. Moore, H. Au, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

AZD2171 (Cediranib) is active in first line metastatic renal cell carcinoma (RCC): Interim results of a phase II trial. A trial of the PMH Phase II Consortium.

I. Tannock, M. Haider, M. Moore, 2007 .

The communal coping model and cancer pain: the roles of catastrophizing and attachment style.

F. Shepherd, M. Moore, G. Rodin, 2012, Journal of Pain.

Characterization of relapse in patients with clinical stage I (CSI) nonseminoma (NS-TC) managed with active surveillance (AS): A large multicenter study.

P. Warde, M. Moore, P. Bedard, 2013 .

Evaluation of Adverse Events Experienced by Older Patients Participating in Studies of Molecularly Targeted Agents Alone or in Combination

G. Pond, A. Oza, H. Hirte, 2006, Clinical Cancer Research.

Chemosensitivity and clinical characteristics of pancreatic malignancies in BRCA mutation carriers.

R. Gershoni-baruch, E. Dagan, E. Friedman, 2013 .

Ampullary cancer ESPAC-3 (v2) trial: A multicenter, international, open-label, randomized controlled phase III trial of adjuvant chemotherapy versus observation in patients with adenocarcinoma of the ampulla of vater.

D. Smith, J. Neoptolemos, C. Bassi, 2011, Journal of Clinical Oncology.

Genomics-driven precision medicine for advanced pancreatic ductal carcinoma (PDAC): Early results from the COMPASS trial (NCT02750657).

R. Moffitt, F. Notta, J. Yeh, 2018 .

A multinational, randomized phase III study of bevacizumab (Bev) with FOLFOX4 or XELOX versus FOLFOX4 alone as adjuvant treatment for colon cancer (CC): Subgroup analyses from the AVANT trial.

R. Salazar, E. Van Cutsem, J. Tabernero, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase I/II Study of GTI-2040 Plus Docetaxel as Second-Line Treatment in Advanced Non-small Cell Lung Cancer: A Study of the PMH Phase II Consortium

G. Pond, Y. Yen, F. Shepherd, 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Reply to D.J. Stewart

G. Pond, M. Moore, L. Siu, 2010 .

Benefits of platinum-based chemotherapy (Pt-chemo) in pancreatic adenocarcinoma (PC) associated with BRCA mutations: A translational case series.

M. Moore, S. Gallinger, B. Tran, 2012 .

A phase II study of cediranib (AZD 2171) in treatment naive patients with progressive unresectable recurrent or metastatic renal cell carcinoma. A trial of the PMH phase 2 consortium

I. Tannock, M. Haider, M. Moore, 2013, Investigational New Drugs.

Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group.

M. Gleave, F. Saad, M. Elhilali, 1998, The New England journal of medicine.

A phase I trial of recombinant human interleukin-1 beta alone and in combination with myelosuppressive doses of 5-fluorouracil in patients with gastrointestinal cancer.

G. Wong, J. Gabrilove, N. Kemeny, 1991, Blood.

Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity.

D. Hedley, M. Moore, M. J. Moore, 2000, Cancer research.

Cluster-randomized trial of early palliative care for patients with metastatic cancer.

I. Tannock, A. Oza, A. Donner, 2012 .

A phase II study of oral ENMD-2076 administered to patients (pts) with advanced soft tissue sarcoma (STS).

H. Mackay, A. Oza, M. Moore, 2013 .

The management of pancreatic cancer. Current expert opinion and recommendations derived from the 8th World Congress on Gastrointestinal Cancer, Barcelona, 2006.

R. Labianca, D. Kerr, P. Johnston, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

A novel biomarker panel examining response to gemcitabine (G) with or without erlotinib (E) for pancreatic cancer (PA) therapy in NCIC clinical trials group PA.3.

A. Koong, G. Heestand, D. Tu, 2014 .

Development and Validation of a Limited Sampling Strategy for 5‐Fluorouracil Given by Bolus Intravenous Administration

M. Moore, J. Thiessen, P Bunting, 1993, Therapeutic drug monitoring.

Erratum: DNA Mismatch Repair Status and Colon Cancer Recurrence and Survival in Clinical Trials of 5-Fluorouracil-Based Adjuvant Therapy (Journal of the National Cancer Institute (2011) 103:11 (863-875))

R. Labianca, D. Sargent, S. Thibodeau, 2011 .

Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas

R. Korn, J. Tabernero, D. V. Von Hoff, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors

Patricia M. LoRusso, Percy, A. Oza, 2008, Investigational New Drugs.

BRAF, PIK3CA, and PTEN status and benefit from cetuximab (CET) in the treatment of advanced colorectal cancer (CRC): Results from NCIC CTG/AGITG CO.17.

P. Gibbs, N. Pavlakis, D. Tu, 2012 .

The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008.

R. Labianca, D. Kerr, J. Berlin, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II trial of perifosine as second line therapy for advanced pancreatic cancer. A study of the Princess Margaret Hospital [PMH] Phase II Consortium

J. Dancey, H. Hirte, D. Hedley, 2005 .

Prognosis model for overall survival in locally advanced unresecable pancreatic carcinoma: An ancillary study of the LAP 07 trial.

M. Moore, D. Goldstein, D. Vernerey, 2015 .

The pharmacokinetics and bioavailability of a new chemosensitizer, SDZ PSC 833, in patients with advanced cancer: 101

P. Goodman, M. Moore, C. Erlichman, 1994 .

Dose-Dependent Increases in Circulating TGF-α and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent

R. Kerbel, M. Moore, Christina R. Lee, 2009, Clinical Cancer Research.

A multi‐institutional phase 2 study of neoadjuvant gemcitabine and oxaliplatin with radiation therapy in patients with pancreatic cancer

Edward J. Kim, K. Griffith, I. Francis, 2013, Cancer.

Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of clinical trials.

I. Tannock, G. Pond, M. Moore, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Comorbidity, age and overall survival in patients with advanced pancreatic cancer - results from NCIC CTG PA.3: a phase III trial of gemcitabine plus erlotinib or placebo.

D. Tu, W. Parulekar, M. Moore, 2012, European journal of cancer.

Quality of life in patients with K‐RAS wild‐type colorectal cancer

D. Tu, M. Moore, H. Au, 2014, Cancer.

Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors.

Jeffrey W. Clark, H. Hirte, H. Lenz, 2007, The oncologist.

Activity of gemcitabine in patients with advanced pancreatic carcinoma: A review

M. Moore, 2022 .

Development of quality indicators of care for patients undergoing hepatic resection for metastatic colorectal cancer using a Delphi process.

J. Barkun, G. Maddern, M. Sherman, 2009, The Journal of surgical research.

Non-risk-adapted surveillance in clinical stage I nonseminomatous germ cell tumors: the Princess Margaret Hospital's experience.

G. Pond, P. Warde, M. Gospodarowicz, 2011, European urology.

Technetium-99m-furifosmin as an agent for functional imaging of multidrug resistance in tumors.

M. Moore, J. Ballinger, T. Muzzammil, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells.

M. Moore, J. Ballinger, N. Hartman, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Multicenter phase II trial of temsirolimus (TEM) and bevacizumab (BEV) in pancreatic neuroendocrine tumor (PNET): Results of a planned interim efficacy analysis.

Helen X. Chen, M. Shah, H. Lenz, 2012 .

When the goal is not cure: A randomized trial of a patient decision aid in advanced colorectal cancer

P. Butow, P. Beale, S. Clarke, 2007 .

Evaluating the Time Toxicity of Cancer Treatment in the CCTG CO.17 Trial

D. Tu, M. Moore, D. Jonker, 2023, JCO oncology practice.

Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial.

M. Sawyer, D. Tu, M. Moore, 2012 .

Metformin for pancreatic cancer.

M. Moore, K. Aung, 2015, The Lancet. Oncology.

Natural History and Chemotherapy Effectiveness for Advanced Adenocarcinoma of the Small Bowel: A Retrospective Review of 113 Cases

G. Pond, A. Oza, M. Moore, 2006, American journal of clinical oncology.